<VariationArchive VariationID="7039" VariationName="NM_013988.3:c.(?_171+24726)_(424+11283_?)del" VariationType="Deletion" Accession="VCV000007039" Version="3" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-07-15" DateCreated="2017-09-10" MostRecentSubmission="2022-12-31">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="22078" VariationID="7039">
      <GeneList>
        <Gene Symbol="PRKN" FullName="parkin RBR E3 ubiquitin protein ligase" GeneID="5071" HGNC_ID="HGNC:8607" Source="submitted" RelationshipType="asserted, but not computed">
          <Location>
            <CytogeneticLocation>6q26</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="6" Accession="NC_000006.12" start="161347417" stop="162727766" display_start="161347417" display_stop="162727766" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="6" Accession="NC_000006.11" start="161768589" stop="163148833" display_start="161768589" display_stop="163148833" Strand="-" />
          </Location>
          <OMIM>602544</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_013988.3:c.(?_171+24726)_(424+11283_?)del</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>6q25.2-q27</CytogeneticLocation>
      </Location>
      <OtherNameList>
        <Name>PRKN, DEL</Name>
        <Name>DEL</Name>
      </OtherNameList>
      <HGVSlist>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000006.12" sequenceAccession="NC_000006" sequenceVersion="12" change="g.(?_161774282)_(162418584_?)del" Assembly="GRCh38">
            <Expression>NC_000006.12:g.(?_161774282)_(162418584_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_013988.3" sequenceAccession="NM_013988" sequenceVersion="3" change="c.(?_171+24726)_(424+11283_?)del">
            <Expression>NM_013988.3:c.(?_171+24726)_(424+11283_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="Allelic variant" ID="602544.0016" DB="OMIM" />
      </XRefList>
      <Comment DataSource="NCBI curation" Type="public">NCBI staff provided an HGVS expression for allelic variant 602544.0016 based on the description by Cesari et al., 2003 (PubMed 12719539) that there was "a common minimal region of loss between markers D6S305 (50%) and D6S1599 (32%)." The locations given are approximate, based on an arbitrary set of primers that have been used to detect those sequences.</Comment>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_013988.3:c.(?_171+24726)_(424+11283_?)del AND Ovarian neoplasm" Accession="RCV000007455" Version="8">
        <ClassifiedConditionList TraitSetID="6377">
          <ClassifiedCondition DB="MedGen" ID="C0919267">Ovarian neoplasm</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="2003-05-13" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2003-05-13" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2017-09-10" MostRecentSubmission="2022-12-31">
        <ReviewStatus>no assertion criteria provided</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">12719539</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="6377" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="5713" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Ovarian neoplasm</ElementValue>
                <XRef ID="HP:0100615" DB="Human Phenotype Ontology" />
                <XRef ID="MONDO:0021068" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Neoplasm of ovary</ElementValue>
                <XRef ID="123843001" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Ovarian Neoplasms</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Ovarian tumor</ElementValue>
                <XRef ID="HP:0100615" DB="Human Phenotype Ontology" />
                <XRef ID="123843001" DB="SNOMED CT" />
              </Name>
              <Citation Type="general" Abbrev="NACB, 2008">
                <ID Source="PubMed">19042984</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2012">
                <ID Source="PubMed">22964825</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2013">
                <ID Source="PubMed">23188549</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2021">
                <ID Source="PubMed">33410258</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2018">
                <ID Source="PubMed">29450531</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2023">
                <URL>https://www.nice.org.uk/guidance/cg122</URL>
                <CitationText>UK NICE Clinical guideline (CG122), Ovarian cancer: recognition and initial management, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2024">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology (NCCN GuidelinesÂ®), Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer, 2024</CitationText>
              </Citation>
              <XRef ID="C0919267" DB="MedGen" />
              <XRef ID="D010051" DB="MeSH" />
              <XRef ID="MONDO:0021068" DB="MONDO" />
              <XRef Type="primary" ID="HP:0100615" DB="Human Phenotype Ontology" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="27655" SubmissionDate="2017-09-07" DateLastUpdated="2022-12-31" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="602544.0016_OVARIAN CANCER, SOMATIC" title="PRKN, DEL_OVARIAN CANCER, SOMATIC" />
        <ClinVarAccession Accession="SCV000027655" DateUpdated="2022-12-31" DateCreated="2013-04-04" Type="SCV" Version="3" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2003-05-13">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>somatic</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">In 3 of 20 ovarian adenocarcinomas (167000), Cesari et al. (2003) found 2 truncating deletions in the PARK2 gene. The findings suggested that PARK2 may be a tumor suppressor gene. An Editorial Expression of Concern was published regarding the article by Cesari et al. (2003).</Attribute>
              <Citation>
                <ID Source="PubMed">12719539</ID>
              </Citation>
              <XRef DB="OMIM" ID="167000" Type="MIM" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="PRKN" />
          </GeneList>
          <Name>PRKN, DEL</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">DEL</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="602544.0016" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">OVARIAN CANCER, SOMATIC</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="27655" TraitType="Disease" MappingType="Name" MappingValue="OVARIAN CANCER, SOMATIC" MappingRef="Preferred">
        <MedGen CUI="C1140680" Name="Ovarian cancer" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

